Small‐molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase‐associated malignant glioma growth

Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury

(2019) Jianxiong Jiang et al.   NEUROPHARMACOLOGY

Discovery of 2-Piperidinyl Phenyl Benzamides and Trisubstituted Pyrimidines as Positive Allosteric Modulators of the Prostaglandin Receptor EP2

(2018) Jianxiong Jiang et al.   ACS Chemical Neuroscience

Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers

(2018) Michael J Curtis et al.   BRITISH JOURNAL OF PHARMACOLOGY

Brain Tumors: Challenges and Opportunities to Cure

(2017) Ingo K. Mellinghoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Adult Glioblastoma

(2017) Brian M. Alexander et al.   JOURNAL OF CLINICAL ONCOLOGY

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

(2017) Simon D Harding et al.   NUCLEIC ACIDS RESEARCH

Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype

(2017) Xu Kang et al.   Scientific Reports

Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus

(2016) Yifeng Du et al.   Expert Review of Neurotherapeutics

Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4

(2016) Katharina Ochs et al.   JOURNAL OF NEUROCHEMISTRY

Cox-2-derived PGE2induces Id1-dependent radiation resistance and self-renewal in experimental glioblastoma

(2016) Peter J. Cook et al.   NEURO-ONCOLOGY

Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus

(2016) Yifeng Du et al.   Expert Review of Neurotherapeutics

Prostaglandin E2 plays a major role in glioma resistance and progression

(2016) Lisa Oliver et al.   Translational Cancer Research

Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?

(2015) G O'Callaghan et al.   BRITISH JOURNAL OF PHARMACOLOGY

Experimental design and analysis and their reporting: new guidance for publication in BJP

(2015) Michael J Curtis et al.   BRITISH JOURNAL OF PHARMACOLOGY

Definition of Prostaglandin E2-EP2 Signals in the Colon Tumor Microenvironment That Amplify Inflammation and Tumor Growth

(2015) X. Ma et al.   CANCER RESEARCH

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

(2015) Santiago Zelenay et al.   CELL

Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus

(2015) Jianxiong Jiang et al.   NEUROBIOLOGY OF DISEASE

Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter

(2015) Jian-Ge Qiu et al.   Oncotarget

Radiation-induced PGE2 sustains human glioma cells growth and survival through EGF signaling

(2015) Emeline Brocard et al.   Oncotarget

COX-2 overexpression increases malignant potential of human glioma cells through Id1

(2015) Kaiming Xu et al.   Oncotarget

Development of second generation EP2 antagonists with high selectivity

(2014) Thota Ganesh et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Lead Optimization Studies of Cinnamic Amide EP2 Antagonists

(2014) Thota Ganesh et al.   JOURNAL OF MEDICINAL CHEMISTRY

The UCSC Cancer Genomics Browser: update 2015

(2014) Mary Goldman et al.   NUCLEIC ACIDS RESEARCH

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

Glioblastoma and Other Malignant Gliomas

(2013) Antonio Omuro   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation

(2013) Jianxiong Jiang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection

(2013) Jianxiong Jiang et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Discovery and Characterization of Carbamothioylacrylamides As EP2 Selective Antagonists

(2013) Thota Ganesh et al.   ACS Medicinal Chemistry Letters

Interleukins in glioblastoma pathophysiology: implications for therapy

(2012) YT Yeung et al.   BRITISH JOURNAL OF PHARMACOLOGY

Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2

(2012) J. Jiang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2

(2011) Xinrong Ma et al.   BREAST CANCER RESEARCH AND TREATMENT

In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP2 receptor antagonist

(2011) KJ af Forselles et al.   BRITISH JOURNAL OF PHARMACOLOGY

Prostanoid Receptors

(2011) Takako Hirata et al.   CHEMICAL REVIEWS

Emotion Recollected in Tranquility: Lessons Learned from the COX-2 Saga

(2010) Tilo Grosser et al.   Annual Review of Medicine

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor

(2010) J. Jiang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE